These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

499 related articles for article (PubMed ID: 34033878)

  • 1. Beyond Lipoprotein(a) plasma measurements: Lipoprotein(a) and inflammation.
    Reyes-Soffer G; Westerterp M
    Pharmacol Res; 2021 Jul; 169():105689. PubMed ID: 34033878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pro-inflammatory interleukin-1 genotypes potentiate the risk of coronary artery disease and cardiovascular events mediated by oxidized phospholipids and lipoprotein(a).
    Tsimikas S; Duff GW; Berger PB; Rogus J; Huttner K; Clopton P; Brilakis E; Kornman KS; Witztum JL
    J Am Coll Cardiol; 2014 May; 63(17):1724-34. PubMed ID: 24530664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipoprotein(a) as a potential causal genetic risk factor of cardiovascular disease: a rationale for increased efforts to understand its pathophysiology and develop targeted therapies.
    Tsimikas S; Hall JL
    J Am Coll Cardiol; 2012 Aug; 60(8):716-21. PubMed ID: 22898069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipoprotein apheresis is an optimal therapeutic option to reduce increased Lp(a) levels.
    Schettler VJJ; Neumann CL; Peter C; Zimmermann T; Julius U; Hohenstein B; Roeseler E; Heigl F; Grützmacher P; Blume H; Klingel R; Vogt A;
    Clin Res Cardiol Suppl; 2019 Apr; 14(Suppl 1):33-38. PubMed ID: 30838552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Supporting evidence for lipoprotein(a) measurements in clinical practice.
    Matveyenko A; Pavlyha M; Reyes-Soffer G
    Best Pract Res Clin Endocrinol Metab; 2023 May; 37(3):101746. PubMed ID: 36828715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enigmatic role of lipoprotein(a) in cardiovascular disease.
    Anuurad E; Enkhmaa B; Berglund L
    Clin Transl Sci; 2010 Dec; 3(6):327-32. PubMed ID: 21167011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipoprotein(a) in Atherosclerotic Diseases: From Pathophysiology to Diagnosis and Treatment.
    Lampsas S; Xenou M; Oikonomou E; Pantelidis P; Lysandrou A; Sarantos S; Goliopoulou A; Kalogeras K; Tsigkou V; Kalpis A; Paschou SA; Theofilis P; Vavuranakis M; Tousoulis D; Siasos G
    Molecules; 2023 Jan; 28(3):. PubMed ID: 36770634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipoprotein(a) catabolism: a case of multiple receptors.
    McCormick SPA; Schneider WJ
    Pathology; 2019 Feb; 51(2):155-164. PubMed ID: 30595508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel insights into Lp(a) physiology and pathogenicity: more questions than answers?
    Koschinsky ML
    Cardiovasc Hematol Disord Drug Targets; 2006 Dec; 6(4):267-78. PubMed ID: 17378772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipoprotein(a) accelerates atherosclerosis in uremic mice.
    Pedersen TX; McCormick SP; Tsimikas S; Bro S; Nielsen LB
    J Lipid Res; 2010 Oct; 51(10):2967-75. PubMed ID: 20584868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipoprotein(a) - Marker for cardiovascular risk and target for lipoprotein apheresis.
    Klingel R; Heigl F; Schettler V; Roeseler E; Grützmacher P; Hohenstein B; Vogt A; Fassbender C; Heibges A; Julius U
    Atheroscler Suppl; 2019 Dec; 40():17-22. PubMed ID: 31818445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of race and ethnicity on lipoprotein(a) levels and cardiovascular risk.
    Reyes-Soffer G
    Curr Opin Lipidol; 2021 Jun; 32(3):163-166. PubMed ID: 33900275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Experimental Animal Models Evaluating the Causal Role of Lipoprotein(a) in Atherosclerosis and Aortic Stenosis.
    Yeang C; Cotter B; Tsimikas S
    Cardiovasc Drugs Ther; 2016 Feb; 30(1):75-85. PubMed ID: 26780907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice.
    Merki E; Graham MJ; Mullick AE; Miller ER; Crooke RM; Pitas RE; Witztum JL; Tsimikas S
    Circulation; 2008 Aug; 118(7):743-53. PubMed ID: 18663084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipoprotein(a): a genetic marker for cardiovascular disease and target for emerging therapies.
    Cesaro A; Schiavo A; Moscarella E; Coletta S; Conte M; Gragnano F; Fimiani F; Monda E; Caiazza M; Limongelli G; D'Erasmo L; Riccio C; Arca M; Calabrò P
    J Cardiovasc Med (Hagerstown); 2021 Mar; 22(3):151-161. PubMed ID: 32858625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Lipoprotein (a)].
    Piolot A; Jacotot B
    Presse Med; 1994 Oct; 23(32):1489-92. PubMed ID: 7824470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High lipoprotein(a) levels and small apolipoprotein(a) size prospectively predict cardiovascular events in dialysis patients.
    Longenecker JC; Klag MJ; Marcovina SM; Liu YM; Jaar BG; Powe NR; Fink NE; Levey AS; Coresh J
    J Am Soc Nephrol; 2005 Jun; 16(6):1794-802. PubMed ID: 15800123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxidized phospholipids in cardiovascular disease.
    Tsimikas S; Witztum JL
    Nat Rev Cardiol; 2024 Mar; 21(3):170-191. PubMed ID: 37848630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipoprotein(a) and cardiovascular disease: current state and future directions for an enigmatic lipoprotein.
    Saeed A; Virani SS
    Front Biosci (Landmark Ed); 2018 Jan; 23(6):1099-1112. PubMed ID: 28930591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipoprotein(a) and its role in inflammation, atherosclerosis and malignancies.
    Orsó E; Schmitz G
    Clin Res Cardiol Suppl; 2017 Mar; 12(Suppl 1):31-37. PubMed ID: 28188431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.